Oxaprozin Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Cardiovascular Effects
Cardiovascular Thrombotic Events: 

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation).

Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see CONTRAINDICATIONS).


NSAIDs, including oxaprozin, can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including oxaprozin, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

Congestive Heart Failure and Edema: 

Fluid retention and edema have been observed in some patients taking NSAIDs. Oxaprozin should be used with caution in patients with fluid retention or heart failure.

Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation: 

NSAIDs, including oxaprozin, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.

NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients treated with neither of these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.

To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.

Renal Effects

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

Advanced Renal Disease

No information is available from controlled clinical studies regarding the use of oxaprozin in patients with advanced renal disease. Therefore, treatment with oxaprozin is not recommended in these patients with advanced renal disease. If oxaprozin therapy must be initiated, close monitoring of the patient's renal function is advisable.

Anaphylactoid Reactions

As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to oxaprozin. Oxaprozin should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS, Pre-existing Asthma). Emergency help should be sought in cases where an anaphylactoid reaction occurs.

Skin Reactions

NSAIDs, including oxaprozin, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.


In late pregnancy, as with other NSAIDs, oxaprozin should be avoided because it may cause premature closure of the ductus arteriosus.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Carefully consider the potential benefits and risks of  oxaprozin tablets USP and other treatment options before deciding to use  oxaprozin tablets USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

Oxaprozin tablets USP are indicated:

• For relief of the signs and symptoms of osteoarthritis. • For relief of the signs and symptoms of rheumatoid arthritis. • For relief of the signs and symptoms of juvenile rheumatoid arthritis.


There is currently no drug history available for this drug.

Other Information

Oxaprozin USP is a nonsteroidal anti-inflammatory drug (NSAID), chemically designated as 4,5-diphenyl-2-oxazole-propionic acid, and has the following chemical structure:

Chemical Structure

The empirical formula for oxaprozin USP is C18H15NO3, and the molecular weight is 293. Oxaprozin USP is a white to off-white powder with a slight odor and a melting point of 162°C to 163°C. It is slightly soluble in alcohol and insoluble in water, with an octanol/water partition coefficient of 4.8 at physiologic pH (7.4). The pKa in water is 4.3.

Oxaprozin tablets USP contain 600 mg of oxaprozin USP.

In addition, each tablet of oxaprozin USP contains the following inactive ingredients: colloidal silicon dioxide, microcrystalline cellulose, hypromellose, methylcellulose, magnesium stearate, polacrilin potassium, starch, polyethylene glycol, titanium dioxide, and polysorbate 80.

Oxaprozin Manufacturers

  • American Health Packaging
    Oxaprozin Tablet [American Health Packaging]
  • Genpharm Inc.
    Oxaprozin (Oxaprozin) Tablet [Genpharm Inc. ]
  • Physicians Total Care, Inc.
    Oxaprozin Tablet [Physicians Total Care, Inc.]
  • Dr. Reddy’s Laboratories Limited
    Oxaprozin Tablet, Film Coated [Dr. Reddy’s Laboratories Limited]
  • Stat Rx Usa Llc
    Oxaprozin Tablet [Stat Rx Usa Llc]
  • Rebel Distributors Corp
    Oxaprozin Tablet, Film Coated [Rebel Distributors Corp]
  • Pd-rx Pharmaceuticals, Inc.
    Oxaprozin Tablet, Film Coated [Pd-rx Pharmaceuticals, Inc.]
  • Lake Erie Medical Dba Quality Care Products Llc
    Oxaprozin Tablet, Film Coated [Lake Erie Medical Dba Quality Care Products Llc]
  • H.j. Harkins Company, Inc.
    Oxaprozin Tablet, Film Coated [H.j. Harkins Company, Inc.]
  • Preferred Pharmaceuticals, Inc
    Oxaprozin Tablet, Film Coated [Preferred Pharmaceuticals, Inc]
  • Unit Dose Services
    Oxaprozin Tablet, Film Coated [Unit Dose Services]
  • Teva Pharmaceuticals Usa Inc
    Oxaprozin Tablet, Film Coated [Teva Pharmaceuticals Usa Inc]
  • Bryant Ranch Prepack
    Oxaprozin Tablet, Film Coated [Bryant Ranch Prepack]
  • Caraco Pharmaceutical Laboratories, Ltd.
    Oxaprozin Tablet [Caraco Pharmaceutical Laboratories, Ltd.]
  • Eon Labs, Inc.
    Oxaprozin Tablet [Eon Labs, Inc.]
  • Greenstone Llc
    Oxaprozin Tablet, Film Coated [Greenstone Llc]
  • Apotex Corp.
    Oxaprozin Tablet, Film Coated [Apotex Corp.]
  • Dispensing Solutions, Inc.
    Oxaprozin Tablet [Dispensing Solutions, Inc.]
  • Clinical Solutions Wholesale
    Oxaprozin Tablet, Film Coated [Clinical Solutions Wholesale]
  • Avkare, Inc.
    Oxaprozin (Oxaprozin) Tablet [Avkare, Inc.]
  • Direct Rx
    Oxaprozin Tablet [Direct Rx]
  • Carilion Materials Management
    Oxaprozin Tablet [Carilion Materials Management]

Login To Your Free Account